Johnson & Johnson's newly formed DePuy Synthes Spine division comes out swinging, touting FDA clearance for a suite of scoliosis-correcting spine devices just weeks after the $19.7 billion merger.
Johnson & Johnson's (NYSE:JNJ) newly formed DePuy Synthes Spine division came out of the gates swinging, announcing its 1st regulatory win less than a month after closing the books on the $19.7 billion merger.
DePuy Synthes Spine this week announced expanded FDA clearance for its Expedium, Viper and Viper2 spine systems for adolescents with idiopathic scoliosis, a condition resulting in abnormal curvature of the spine, typically in children between the ages of 10 and 18. The devices were already cleared for adults.
"This FDA clearance is an important milestone for us as a company, and is also important for adolescent patients who will have greater access to the latest technology available if they require spine surgery for their scoliosis," DePuy Synthes worldwide president Namal Nawana said in prepared remarks.